SELLAS Life Sciences Group, Inc. Common Stock
Here’s whether SELLAS Life Sciences Group, Inc. Common Stock (SLS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+8.06% over 10 days); strong 1-year return of +778.4%; 3-month momentum positive (+98.7%). Concerns: RSI 79 — overbought, elevated pullback risk. Currently 2.6% off its 52-week high. Score: +5/7.
SLS is in a confirmed uptrend, trading above both its 50-day ($11.70) and 200-day ($6.18) moving averages. With an RSI of 78.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +778.4% compares to +20.5% for SPY (beat the market by 757.9%).